Prostate cancer is the most common cancer in males in western societies. In spite of the successful first line treatment using surgery, radiation therapy, antiandrogen treatment or combination therapy the disease progresses towards a hormone refractory state where the only effective treatment is chemotherapy which prolongs overall survival, however it is not curative. The resistance that hormone refractory disease displays highlights the importance of developing new targeted therapies which may be curative or at least may improve the patient's quality of life and overall survival. Current chemotherapeutic regimens used in prostate cancer treatment mostly contain agents that induce DNA damage and specifically double strand breaks, such as Doxorubicin, mitoxantrone and etoposide.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:500921 |
| Date | January 2009 |
| Creators | Shaheen, Fadhel Sulaiman |
| Publisher | University of Newcastle Upon Tyne |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
Page generated in 0.0016 seconds